BIOPAS ARGENTINA S.A, el laboratorio que comercializa el producto Rivotril® (Clonazepam) elaborado por laboratorios Roche, informa que, a pesar de la creciente demanda, este fármaco se encuentra disponible en las farmacias de todo el país con las siguientes presentaciones: Rivotril® (Clonazepam) 0,5 mg y Rivotril® (Clonazepam) 2 mg.

Under the terms of the agreements, Acorda will receive a significant, double-digit, tiered percentage of the selling price of INBRIJA in Latin America in exchange for supply of the product. Acorda will also receive sales-based milestones. Biopas will have the exclusive distribution rights to INBRIJA in nine countries within Latin America, including Brazil and Mexico

Under the terms of the agreement, Biopas will have exclusive rights to distribute, market, and seek reimbursement for Sialanar® within its paediatric indication in Argentina, Chile, Ecuador, Peru, Panama, Costa Rica, Colombia and Mexico. It is estimated that approximately 19,000 children with neurodisabilities suffer today from sialorrhoea in this Latin American region.

BIOPAS, a leading and unique Latin American biopharmaceutical company focused on in-licensing and commercialization of specialty pharmaceuticals - to the exclusion of any generic and/or branded generic drugs - that address unmet medical needs in the region, announced today the full launch of its Brazilian operations with the exclusive distribution of RIVOTRIL® beginning in November, thus expanding its on-going strategic collaboration with CHEPLAPHARM ARZNEIMITTEL GmbH into the Brazilian territory.

BIOPAS, uma companhia biofarmacêutica líder e única na América Latina, focada no licenciamento e comercialização de medicamentos especializados e de referência no mercado farmacêutico, que busca endereçar necessidades médicas não